Radiovirotherapy: Principles and Prospects in Oncology

Touchefeu, Yann; Franken, Philippe; Harrington, Kevin

doi:10.2174/1381612811209023313

Cited by 33 publications

(32 citation statements)

References 91 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Current cancer treatments involve combination therapies such as radioimmunotherapy [29,58], radiovirotherapy [15,59], and immunotherapy combined with targeted therapies [23,41,63], to name but a few. Presently, despite aggressive treatments including combination therapies, most cancers often recur due to their resistance to conventional therapies and limitations to effective therapies [60].…”

Section: Introductionmentioning

confidence: 99%

Modelling the spatiotemporal dynamics of chemovirotherapy cancer treatment

Malinzi

Eladdadi

Sibanda

2017

Journal of Biological Dynamics

View full text Add to dashboard Cite

Chemovirotherapy is a combination therapy with chemotherapy and oncolytic viruses. It is gaining more interest and attracting more attention in the clinical setting due to its effective therapy and potential synergistic interactions against cancer. In this paper, we develop and analyse a mathematical model in the form of parabolic nonlinear partial differential equations to investigate the spatiotemporal dynamics of tumour cells under chemovirotherapy treatment. The proposed model consists of uninfected and infected tumour cells, a free virus, and a chemotherapeutic drug. The analysis of the model is carried out for both the temporal and spatiotemporal cases. Travelling wave solutions to the spatiotemporal model are used to determine the minimum wave speed of tumour invasion. A sensitivity analysis is performed on the model parameters to establish the key parameters that promote cancer remission during chemovirotherapy treatment. Model analysis of the temporal model suggests that virus burst size and virus infection rate determine the success of the virotherapy treatment, whereas travelling wave solutions to the spatiotemporal model show that tumour diffusivity and growth rate are critical during chemovirotherapy. Simulation results reveal that chemovirotherapy is more effective and a good alternative to either chemotherapy or virotherapy, which is in agreement with the recent experimental studies. ARTICLE HISTORY

show abstract

Section: Introductionmentioning

confidence: 99%

Modelling the spatiotemporal dynamics of chemovirotherapy cancer treatment

Malinzi

Eladdadi

Sibanda

2017

Journal of Biological Dynamics

View full text Add to dashboard Cite

show abstract

“…Similarly, incorporation of other high-energy alpha particles (e.g., 213 Bi, 211 At, 225 Ac) is under investigation [164]. Other novel combined treatment methods such as radiovirotherapy (use of oncolytic viruses to deliver radionuclide therapy into infected cancer cells) are also exciting recent developments [165]. …”

Section: Future Prospectsmentioning

confidence: 99%

Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment

Jadvar

2017

American Journal of Roentgenology

View full text Add to dashboard Cite

Objective This article reviews recent developments in targeted radionuclide therapy (TRT) approaches directed to malignant liver lesions, bone metastases, neuroendocrine tumors, and castrate-resistant metastatic prostate cancer and discusses challenges and opportunities in this field. Conclusion TRT has been employed since the first radioiodine thyroid treatment almost 75 years ago. Progress in the understanding of the complex underlying biology of cancer and advances in radiochemistry science, multimodal imaging techniques including the concept of “see and treat” within the framework of theranostics, and universal traction with the notion of precision medicine have all contributed to a resurgence of TRT.

show abstract

“…8, 19 However, off-target damage, restricted replication and incompetence to target smaller metastases need to be further addressed. 20 …”

Section: Introductionmentioning

confidence: 99%

HSV-NIS, an oncolytic herpes simplex virus type 1 encoding human sodium iodide symporter for preclinical prostate cancer radiovirotherapy

Nakashima

Decklever

et al. 2013

Cancer Gene Ther

View full text Add to dashboard Cite

Several clinical trials have shown that oncolytic herpes simplex virus type 1 (oHSV-1) can be safely administered to patients. However, virus replication in tumor tissue has generally not been monitored in these oHSV clinical trials, and the data suggest that its oncolytic potency needs to be improved. To facilitate noninvasive monitoring of the in vivo spread of an oHSV and to increase its antitumor efficacy, the gene coding for human sodium iodide symporter (NIS) was incorporated into a recombinant oHSV genome and the corresponding virus (oHSV-NIS) rescued in our laboratory. Our data demonstrate that a human prostate cancer cell line, LNCap, efficiently concentrates radioactive iodine after the cells have been infected in vitro or in vivo. In vivo replication of oHSV-NIS in tumors was noninvasively monitored by computed tomography/single-photon emission computed tomography imaging of the biodistribution of pertechnetate and was confirmed. LNCap xenografts in nude mice were eradicated by intratumoral administration of oHSV-NIS. Systemic administration of oHSV-NIS prolonged the survival of tumor-bearing mice, and the therapeutic effect was further enhanced by administration of 131I after the intratumoral spread of the virus had peaked. oHSV-NIS has the potential to substantially enhance the outcomes of standard therapy for patients with prostate cancer.

show abstract

Radiovirotherapy: Principles and Prospects in Oncology

Cited by 33 publications

References 91 publications

Modelling the spatiotemporal dynamics of chemovirotherapy cancer treatment

Modelling the spatiotemporal dynamics of chemovirotherapy cancer treatment

Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment

HSV-NIS, an oncolytic herpes simplex virus type 1 encoding human sodium iodide symporter for preclinical prostate cancer radiovirotherapy

Contact Info

Product

Resources

About